Captopril Articles
Domestic vs JV drug prices in China differ
20 August 2007
Headlines 25 years ago this week....
10 April 2006
Novartis' Diovan gets EU nod for heart attack
16 May 2005
Novartis' Diovan gets UK OK for new use
1 November 2004
Novartis files for new use of Diovan
9 February 2004
Generic drug sales take off in Brazil
3 March 2003
PhRMA R&D spending claims attacked
25 July 2001
Novartis completes VALIANT enrolment
10 July 2001
Chinese joint-venture sales in 1999
22 February 2000
Magainin's squalamine in diabetic retinopathy
21 January 2000
Cozaar disappoints in heart failure study
11 November 1999
Beyond ACE inhibition: the future of angiotensin I inhibitors
11 February 1999
Prospects For Emerging Euro Generics Markets
16 December 1998
UKPDS - Implications For Type 2 Diabetes Treatment
17 September 1998
India's Wockhardt Expands With Take Over Of Merind
23 March 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
Candesartan CHF Trial Stopped On Mortality Concerns
24 November 1997
Bayvit Launched First Generic Product, In Spain
6 November 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
Chinese Sales of Joint-Venture Drugs Growing
26 September 1997
Cardiovascular Market And MNCs In Hungary
29 August 1997
B-MS Plans To Launch Three New Drugs A Year
17 June 1997
Surge In Exports At Egis In First Quarter
30 May 1997
Generics Market Growth Twice That Of Retail Sales
7 April 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Cardiac Disease Market Opportunities
3 February 1997
Russian Drug Output Fails To Meet Demand
27 January 1997
NEW YORK STOCK COMMENT
28 October 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Bristol-Myers Squibb Pirating Drugs?
7 October 1996
Schwarz Pharma Achieves Sharp Growth
9 September 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Patent Expiries Set To Drive Generics Boom
22 July 1996
1996 A Transitional Year For Royce
24 June 1996
"Generics Could Save Canadians C$30 Mill"
10 June 1996
Egis Reports Growth In 1996 1st Qtr
3 June 1996
11% 1st-Qtr EPS Rise From US Drug Cos
15 April 1996
Corporate Ranking - A New Order For 1995
1 April 1996
Copley's Generic Captopril
26 February 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
Gneric Captopril Approvals
19 February 1996
FDA Panel Verdict On Calcium Blockers
5 February 1996
Apothecon : captopril exclusivity news
22 January 1996
Lisinopril Cleared Post-MI In USA
4 December 1995
Ciba Postpones Generic Captopril Introduction
27 November 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Teva Pharma: captopril......
9 October 1995
Royce Set To Market Captopril In 1995?
4 September 1995
Generics: A Passage Through Time
4 September 1995
Mova's cimetidine
21 August 1995
Merck & Co Sues FDA, PTO Over GATT Ruling
14 August 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Bristol-Myers research operations
31 July 1995
Congress Faces Generic Drug Pressure Over GATT
24 July 1995
The Drug Industry And The Nafta Experience
10 July 1995
FDA Rules Against Generics On GATT
5 June 1995
Disease ManagementThe Way Forward
15 May 1995
New York stock comment
15 May 1995
Gastrointestinals Top Taiwan Market
8 May 1995
ISIS-4 Results Confirm ACEI Benefits In MI
27 March 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
BASF Generics Launch
20 March 1995
Dutch Govt Has Mistaken Impression Of Drug Prices
13 March 1995
Generics "Disappointment" For Brand-Name Firms
20 February 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
$25 Bill Latin American Pharma Market In 2000
9 January 1995
Drug Cos Benefit From GATT Patent Provisions
2 January 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Generics To Lead US Managed Care "Soon"
17 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
Losartan Gains First Approval In Sweden
10 October 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
LOSARTAN OFFERS BETTER CONTROL
4 July 1994
ANTIHYPERTENSIVES FAIL TROUGH-PEAK CRITERIA
20 June 1994
TAIWAN DRUG MARKET IN 1993
13 June 1994
B-MS TAKES STAKE IN GEHE AFFILIATE
16 May 1994
B-MS TO MARKET GLUCOPHAGE IN USA
9 May 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
N AMERICAN PHARMA MARKET STUDIED
28 February 1994
CAPOTEN GAINS ADDITIONAL LICENSE IN UK
21 February 1994
COST-CONTAINMENT, A BITTER PILL FOR INDUSTRY
21 February 1994
CAPOTEN APPROVED FOR DIABETES
7 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
ENALAPRIL GETS POST-MI INDICATION
22 November 1993
ACCUPRIL APPROVED FOR CHF INDICATION
15 November 1993
ISIS-4 STUDY YIELDS MIXED RESULTS
15 November 1993
NEW YORK STOCK COMMENT
15 November 1993
FURTHER RESULTS FROM THE GISSI-3 STUDY
15 November 1993
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
